Cellectar Biosciences Inc. (CLRB)
$2.54
$0.00 (0.00%)As on 27-Aug-2026 16:00EDT
Market cap
$24 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.2 %
-
ROCE
-- %
-
Industry P/E
37.31
-
EV/EBITDA
-3.3
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-4.6
-
Face value
--
-
Shares outstanding
9,452,108
10 Years Aggregate
CFO
$-153.59 Mln
EBITDA
$-178.43 Mln
Net Profit
$-165.77 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Cellectar Biosciences (CLRB)
| -13.9 | 5.4 | -18.1 | -46.6 | -63.5 | -61.2 | -54.7 |
|
BSE Sensex*
| -8.8 | 0.6 | 1.8 | -4.4 | 6.0 | 6.6 | 10.8 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Cellectar Biosciences (CLRB)
| -67.1 | -89.0 | 62.0 | -74.1 | -68.3 | -7.6 | 45.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Cellectar Biosciences (CLRB)
|
2.5 | 24.5 | 0.0 | -22.3 | -- | -112.2 | -- | 0.8 |
| 18.0 | 6,238.0 | 3,117.6 | 157.4 | 14.7 | -- | 37.3 | 188.9 | |
| 206.3 | 10,883.2 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 130.9 | |
| 78.7 | 15,932.7 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 116.9 | 13,215.0 | 830.8 | 54.9 | 3.2 | 8.1 | 271.7 | 18.7 | |
| 12.2 | 10,087.6 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 28.8 | 2.5 | |
| 24.5 | 11,971.8 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.8 | |
| 284.5 | 5,707.4 | 290.5 | 197.2 | 82.5 | 19.9 | 29.6 | 5.9 | |
| 69.9 | 6,142.1 | 450.9 | 138.6 | 39.1 | 115.6 | 49 | 31.5 | |
| 153.1 | 9,129.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 20.5 |
Shareholding Pattern
View DetailsAbout Cellectar Biosciences (CLRB)
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate... is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 121125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based radioconjugate program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey. Read more
-
President, CEO & Director
Mr. James V. Caruso
-
President, CEO & Director
Mr. James V. Caruso
-
Headquarters
Florham Park, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Cellectar Biosciences (CLRB)
What is the current share price of Cellectar Biosciences Inc (CLRB) Today?
The share price of Cellectar Biosciences Inc (CLRB) is $2.54 (NASDAQ) as of 27-Aug-2026 16:00 EDT. Cellectar Biosciences Inc (CLRB) has given a return of -63.49% in the last 3 years.
What is the current PB & PE ratio of Cellectar Biosciences Inc (CLRB)?
Since, TTM earnings of Cellectar Biosciences Inc (CLRB) is negative, P/E ratio is not available.
The P/B ratio of Cellectar Biosciences Inc (CLRB) is 0.80 times as on 21-Aug-2026, a 90 discount to its peers’ median range of 7.75 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.57 |
1.26 |
2024 |
-0.01 |
0.03 |
2023 |
-0.04 |
-0.13 |
2022 |
-0.02 |
0.06 |
2021 |
-0.01 |
0.00 |
What is the 52 Week High and Low of Cellectar Biosciences Inc (CLRB)?
The 52-week high and low of Cellectar Biosciences Inc (CLRB) are Rs 6.52 and Rs 2.20 as of 28-Aug-2026.
What is the market cap of Cellectar Biosciences Inc (CLRB)?
Cellectar Biosciences Inc (CLRB) has a market capitalisation of $ 24 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Cellectar Biosciences Inc (CLRB)?
Before investing in Cellectar Biosciences Inc (CLRB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.